PHARMACY POLICY STATEMENT
North Carolina Marketplace

DRUG NAME	**Xgeva (denosumab)**
BILLING CODE	J0897
BENEFIT TYPE	Medical
SITE OF SERVICE ALLOWED	Office/Outpatient Hospital
STATUS	Prior Authorization Required

Xgeva (denosumab) was initially approved by the FDA in 2010 and is a monoclonal antibody that inhibits the RANK ligand (RANKL). It is indicated for the prevention of skeletal-related events in patients with multiple myeloma

Multiple Myeloma, Bone Metastasis from Solid Tumors, and Hypercalcemia of Malignancy

Any request for cancer or hypercalcemia of malignancy must be submitted through NantHealth/Eviti portal.

CareSource considers Xgeva (denosumab) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
08/13/2020	New policy for Xgeva created
04/26/2022	Transferred to new template. Added QL. Updated references. Added specialist and diagnostic confirmation. Modified wording of renewal criteria. Shortened initial approval duration from 12 mo to 6 mo.

References:

1. Xgeva [prescribing information]. Thousand Oaks, CA: Amgen Inc.; June, 2020.
2. van der Heijden L, Dijkstra PD, van de Sande MA, et al. The clinical approach toward giant cell tumor of bone. *Oncologist*. 2014;19(5):550-561. doi:10.1634/theoncologist.2013-0432.
3. van der Heijden L, Dijkstra S, van de Sande M, Gelderblom H. Current concepts in the treatment of giant cel m H.. giant